PDD 00017272

Pricing Availability   Qty
Description: Potent PARG inhibitor
Chemical Name: 1-[(2,4-Dimethyl-5-thiazolyl)methyl]-1,2,3,4-tetrahydro-N-(1-methylcyclopropyl)-3-[(2-methyl-5-thiazolyl)methyl]-2,4-dioxo-6-quinazolinesulfonamide
Purity: ≥98% (HPLC)
Literature (1)

Biological Activity for PDD 00017272

PDD 00017272 is a potent poly (ADP ribose) glycohydrolase (PARG) inhibitor (IC50 values are 4.8 nM in biochemical assay and 9.2 nM in cell based assay).

Licensing Information

Sold under license from Cancer Research Technology Ltd (Ximbio).

Technical Data for PDD 00017272

M. Wt 531.66
Formula C23H25N5O4S3
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 1945950-20-8
PubChem ID 134169694
Smiles CC1=NC=C(S1)CN2C(N(C3=CC=C(S(=O)(NC4(CC4)C)=O)C=C3C2=O)CC5=C(N=C(S5)C)C)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for PDD 00017272

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 10.63 20 with gentle warming

Preparing Stock Solutions for PDD 00017272

The following data is based on the product molecular weight 531.66. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.2 mM 9.4 mL 47.02 mL 94.05 mL
1 mM 1.88 mL 9.4 mL 18.81 mL
2 mM 0.94 mL 4.7 mL 9.4 mL
10 mM 0.19 mL 0.94 mL 1.88 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for PDD 00017272

References are publications that support the biological activity of the product.

Waszkowycz et al (2018) Cell-active small molecule inhibitors of the DNA-damage repair enzyme poly(ADP-ribose) glycohydrolase (PARG): discovery and optimization of orally bioavailable quinazolinedione sulfonamides. J.Med.Chem. 61 10767 PMID: 30403352

If you know of a relevant reference for PDD 00017272, please let us know.

View Related Products by Product Action

View all Poly(ADP-ribose) Glycohydrolase Inhibitors

Keywords: PDD 00017272, PDD 00017272 supplier, PDD00017272, PARG, inhibitors, poly, ADP, ribose, glycohydrolase, inhibits, PDDX-004, potent, Poly(ADP)-ribose, Glycohydrolase, 7006, Tocris Bioscience

Citations for PDD 00017272

Citations are publications that use Tocris products.

Currently there are no citations for PDD 00017272. Do you know of a great paper that uses PDD 00017272 from Tocris? Please let us know.

Reviews for PDD 00017272

There are currently no reviews for this product. Be the first to review PDD 00017272 and earn rewards!

Have you used PDD 00017272?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.